Published 10 days ago • loading... • Updated 9 days ago

FDA-Approved Denosumab Biosimilars Expand Oncology Options in US

Celltrion USA launches 2 denosumab biosimilars, Stoboclo and Osenvelt, enhancing treatment options for osteoporosis and cancer-related skeletal issues.

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

3 Articles

targetedonc.com

FDA-Approved Denosumab Biosimilars Expand Oncology Options in US

Celltrion USA launches 2 denosumab biosimilars, Stoboclo and Osenvelt, enhancing treatment options for osteoporosis and cancer-related skeletal issues.

9 days ago

Read Full Article

centerforbiosimilars.com

Two More Pairs of Denosumab Biosimilars Enter US Market

The US biosimilar market expands with new denosumab options, enhancing treatment for patients with osteoporosis and bone-related metastases.

10 days ago

Read Full Article

curetoday.com

FDA Approves Stoboclo and Osenvelt as Biosimilars Across Some Cancers

Stoboclo and Osenvelt, FDA-approved biosimilars of Prolia and Xgeva, are now available in the U.S. for variois cancers and cancer-related bone conditions.

10 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year